Romosozumab improves lumbar spine BMD and bone strength greater than alendronate as assessed by quantitative computed tomography and finite element analysis in the ARCH trial

Romosozumab improves lumbar spine BMD and bone strength greater than alendronate as assessed by quantitative computed tomography and finite element analysis in the ARCH trial

Bibliographic Details
Main Authors:	Jacques P. Brown, Arkadi Chines, Roland Chapurlat, Joseph Foldes, Xavier Nogues, Roberto Civitelli, Tobias De Villiers, Fabio Massari, Cristiano Zerbini, Wenjing Yang, Chris Recknor, Cesar Libanati
Format:	Article
Language:	English
Published:	Elsevier 2020-10-01
Series:	Bone Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352187220300863

Similar Items

Skeletal responses to romosozumab after 12 months of denosumab
by: Michael R. McClung, et al.
Published: (2021-07-01)

Lumbar spine and proximal femur BMD values in Turkish girls and the effect of precocious puberty on BMD.
by: Ersoy Kekilli, et al.
Published: (2012-09-01)

Alendronate increases BMD at appendicular and axial skeletons in patients with established osteoporosis
by: Au Szeki, et al.
Published: (2007-05-01)

Concordane of OSTA and lumbar spine BMD by DXA in identifying risk of osteoporosis
by: Cai YunHua, et al.
Published: (2006-11-01)

Extensive modeling-based bone formation after 2 months of romosozumab treatment: Results from the FRAME clinical trial
by: Erik F. Eriksen, et al.
Published: (2020-10-01)

Romosozumab for the treatment of osteoporosis
by: Michael R. McClung
Published: (2018-03-01)

Comparison between the MDCT and the DXA scanners in the evaluation of BMD in the lumbar spine densit
by: Jalil Pirayesh Islamian, et al.
Published: (2016-09-01)

Relationship of homocysteine levels with lumbar spine and femur neck BMD in postmenopausal women
by: Elton Bahtiri, et al.
Published: (2015-10-01)

Romosozumab and cardiovascular safety in Japan
by: Yasuhiro Takeuchi
Published: (2021-09-01)

Kinetic reconstruction of the cancellous (Cn) and endocortical (Ec) remodelling unit reveals a net positive bone balance (BB) after 12 months of treatment with romosozumab
by: Erik F. Eriksen, et al.
Published: (2021-04-01)

Glucocorticoid-Induced Osteoporosis: The Potential Role of Romosozumab
by: Jacqueline So, et al.
Published: (2020-12-01)

Profile of romosozumab and its potential in the management of osteoporosis
by: Lim SY, et al.
Published: (2017-04-01)

Denosumab versus romosozumab for postmenopausal osteoporosis treatment
by: Tomonori Kobayakawa, et al.
Published: (2021-06-01)

Comparison of the Spine and Hip BMD Assessments Derived from Quantitative Computed Tomography
by: Xiao-Hui Ma, et al.
Published: (2015-01-01)

The Effect of 1 Year of Romosozumab on the Incidence of Clinical Vertebral Fractures in Postmenopausal Women With Osteoporosis: Results From the FRAME Study
by: Piet Geusens, et al.
Published: (2019-10-01)

Romosozumab: A new anabolic arrow in quiver for management of osteoporosis
by: Alok Singh, et al.
Published: (2020-01-01)

Balancing the risks and benefits of biologic drugs in rheumatic disease: the case for romosozumab?
by: David M. Reid
Published: (2020-01-01)

Romosozumab vid behandling av osteoporos : Effekten på bentäthet och frakturrisk
by: Johansson, Klara
Published: (2020)

Deep learning spine segmentation to get accurate and relevant BMD and TBS values: The OsteoLaus study
by: François De Guio, et al.
Published: (2020-10-01)

Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada
by: Brown, J.P, et al.
Published: (2022)

Nickel alendronate
by: Ma&#322;gorzata Sikorska, et al.
Published: (2012-06-01)

Romosozumab in Postmenopausal Korean Women with Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study
by: Ki-Hyun Baek, et al.
Published: (2021-02-01)

Effect of switching administration of alendronate after teriparatide for the prevention of BMD loss around the implant after total hip arthroplasty, 2-year follow-up: a randomized controlled trial
by: Akira Morita, et al.
Published: (2020-01-01)

Romosozumab and blosozumab: alternative drugs of mechanical strain-related stimulus toward a cure for osteoporosis
by: Toshihiro eSugiyama, et al.
Published: (2015-04-01)

QUS of phalanx, DXA, BMD, Osteoporosis
by: A Soltani, et al.
Published: (2004-11-01)

QUS of phalanx, DXA, BMD, Osteoporosis
by: A Soltani, et al.
Published: (2004-03-01)

Psychosocial support in treatment of BMD I
by: Taban Habiballah, et al.
Published: (2006-02-01)

Research lifestyle factors and BMD of freshmen.
by: Chin-Fu Tsay, et al.
Published: (2014)

Esophageal ulcer and alendronate
by: Angelo Paulo Ferrari Junior, et al.

Response rates for hip, femoral neck, and lumbar spine bone mineral density in patients treated with abaloparatide followed by alendronate: Results from phase 3 ACTIVExtend
by: Chad L. Deal, et al.
Published: (2019-12-01)

Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation
by: Sarah Davis, et al.
Published: (2020-06-01)

Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation
by: Sarah Davis, et al.
Published: (2020-06-01)

Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: A prospective cohort study
by: Tomonori Kobayakawa, et al.
Published: (2021-06-01)

BMI and EAT-26, Predictors for Low BMD?
by: Sonya Sanderson, et al.
Published: (2012-01-01)

Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: A case report
by: Masafumi Kashii, et al.
Published: (2020-12-01)

FRAX Calculated without BMD Resulting in a Higher Fracture Risk Than That Calculated with BMD in Women with Early Breast Cancer
by: Rizky Suganda Prawiradilaga, et al.
Published: (2018-01-01)

Use of alendronate in the therapy of osteoporosis
by: O. B. Ershova
Published: (2020-01-01)

The Effect of Alendronate in Male Osteoporosis
by: Özlem El, et al.
Published: (2004-12-01)

Evaluation of Cerebral Cortex Function in Clients with Bipolar Mood Disorder I (BMD I) Compared With BMD II Using QEEG Analysis
by: Ali Khaleghi, et al.
Published: (2016-02-01)

Advantages of lateral BMD DEXA measurement and concomitant lateral spinal imaging at the point of service over conventional PA measurement in the estimation of BMD
by: Paul Sneider
Published: (2003-06-01)